Literature DB >> 670346

Determination of trimethoprim and sulfamethoxazole (co-trimoxazole) in body fluids of man by means of high-performance liquid chromatography.

T B Vree, Y A Hekster, A M Baars, J E Damsma, E V Kleijin.   

Abstract

A high-performance liquid chromatographic method for the determination of trimethoprim, sulfamethoxazole and its metabolite and a series of structurally related sulfonamides is described. The half-life time of elimination of sulfamethoxazole and its metabolite N4-acetylsulfamethoxazole is 9 h for both compounds. The renal excretion rate of sulfamethoxazole depends strongly on the urinary pH. The renal excretion rate of the metabolite N4-acetylsulfamethoxazole is not dependent on the urinary pH.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 670346     DOI： 10.1016/s0378-4347(00)81294-3

Source DB:  PubMed          Journal:  J Chromatogr


  13 in total

1.  Development and validation of an HPLC method for simultaneous determination of trimethoprim and sulfamethoxazole in human plasma.

Authors:  Esin Sayar; Selma Sahin; Semsettin Cevheroglu; A Atilla Hincal
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-09       Impact factor: 2.441

2.  Pharmacokinetics of sulphamethoxazole in man: effects of urinary pH and urine flow on metabolism and renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole.

Authors:  T B Vree; Y A Hekster; A M Baars; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  The comparison of some pharmacokinetic parameters of sulphadimethoxine estimated by high performance liquid chromatography and three spectrophotometric methods.

Authors:  A Klimowicz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jul-Sep       Impact factor: 2.441

4.  Antimicrobial therapy of experimental Legionella micdadei pneumonia in guinea pigs.

Authors:  A W Pasculle; J N Dowling; F N Frola; D A McDevitt; M A Levi
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

5.  Pharmacokinetics of N1-acetyl- and N4-acetylsulphamethoxazole in man.

Authors:  T B Vree; Y A Hekster; J E Damsma; E van der Kleijn; W J O'Reilly
Journal:  Clin Pharmacokinet       Date:  1979 Jul-Aug       Impact factor: 6.447

6.  Sulfonamide and trimethoprim concentrations in human serum and skin blister fluid.

Authors:  J N Bruun; N Ostby; J E Bredesen; P Kierulf; P K Lunde
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of co-trimazine.

Authors:  T Bergan; B Ortengren; D Westerlund
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

8.  Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

Authors:  L E Ramsay; J H Silas; J D Ollerenshaw; G T Tucker; F C Phillips; S Freestone
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

10.  Steady state pharmacokinetics of trimethoprim 300 mg once daily in healthy volunteers assessed by two independent methods.

Authors:  B Odlind; P Hartvig; K E Fjellström; B Lindström; S Bengtsson
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.